New research indicates that 10-kHz spinal cord stimulation not only reduces pain in patients with painful diabetic neuropathy but may also improve nerve sensation and fibre density, suggesting potential broader neurological benefits.
High-frequency spinal cord stimulation may offer more than pain relief for people with painful diabetic neuropathy, according to a study published online in Diabetes Care that found measurable gains in sensation and nerve-fibre density alongside lower pain scores. The research, led by Robert W. Hurley of Wake Forest University in Winston-Salem, North Carolina, adds to growing evidence that 10-kHz spinal cord stimulation can help patients whose symptoms persist despite standard drug treatment.
In the study, 91 people with painful diabetic neuropathy were assigned to conventional medical management alone or to that treatment plus 10-kHz spinal cord stimulation. Among those who received the device therapy, most of the participants who completed the temporary trial achieved at least 50% relief in lower-limb pain, while only a small minority in the medication-only group reached that threshold. At six months, sensory improvement on the modified Toronto Clinical Neuropathy Score was also more common in the stimulation group, and a measure of lower-calf nerve-fibre density rose rather than falling.
The findings build on earlier research suggesting the therapy can be effective for difficult-to-treat diabetic nerve pain. A review in Nature Reviews Neurology in 2021 described a larger multicentre trial in which 79% of patients given 10-kHz stimulation plus conventional care achieved at least half pain relief, compared with 5% in the control group. More recent work published in Pain Medicine and the Journal of Diabetes Science and Technology has also reported durable pain reduction, better sleep and quality of life, and signs of neurological improvement over longer follow-up periods.
Hurley said the pain results were expected, but the sensory changes and nerve-fibre data were especially encouraging. He added that the results suggest the treatment may affect more than symptoms alone, although longer follow-up will be needed to see whether the benefits last and what they mean in practice. The study’s authors said eight of 10 secondary end points were met, including measures linked to sleep and quality of life, strengthening the case for further research in a condition that can be both painful and disabling.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
